[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617011":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":20,"collaborators":11,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":28,"acronym":11,"eligibilityCriteria":29,"healthyVolunteers":26,"sex":30,"minAge":31,"maxAge":11,"enrollmentInfo":32,"targetDuration":11,"studyType":35,"phases":36,"briefSummary":38,"conditions":39,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":11},{"fullName":5,"class":6},"Hexsel Dermatology Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Medicated Nail Lacquer","EXPERIMENTAL",null,[13],"Drug: Topical 2% Tofacitinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Topical 2% Tofacitinib","Following participant selection, confirmation of eligibility criteria, and completion of the baseline clinical assessment (Day 0), each participant will receive one bottle of nail lacquer containing Tofacitinib 2% for home use throughout the study period. Application of the investigational product will be the responsibility of the participant and must be performed once daily, in accordance with the instructions provided by the research team. Prior to each new application, the participant must completely remove the previous layer of nail lacquer, ensuring that the nail surface is clean and dry. After removal, a new uniform layer of the product should be applied to the affected nail(s). The product must be used daily and continuously for the entire duration of the study, in compliance with the schedule established in the study protocol.",[9],{"type":21,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Doris Hexsel","Dr","100617011","phase-2-topical-use-of-2-tofacitinib-for-nail-psoriasis-an-exploratory-clinical-study-100617011",false,"NCT07313072","Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study","Inclusion Criteria: Age ≥ 18 years;\n\n* Presence of nail psoriasis in at least one fingernail or toenail;\n* Patients not using systemic medication, or without adequate response to systemic medication after at least 6 months of use;\n* Ability to read, understand, and sign the Informed Consent Form (ICF) and the Consent Form for Images, Presentations, and Scientific Publications.\n\nExclusion Criteria: Pregnant or breastfeeding women or those planning to become pregnant during the study period;\n\n* History of sensitivity to any components of the study product;\n* Initiation of systemic medication for nail psoriasis less than six months prior.","ALL","18 Years",{"count":33,"type":34},10,"ESTIMATED","INTERVENTIONAL",[37],"PHASE2","To evaluate the efficacy and safety of topical 2% tofacitinib nail lacquer in nail psoriasis, using the NAPSI and DLQI scales before and after 26 weeks of treatment.",[40],"Nail Psoriasis","NOT_YET_RECRUITING","2026-03-16",{"date":44,"type":45},"2026-03-18","ACTUAL",{"date":47,"type":34},"2026-03",{"date":49,"type":34},"2027-03",{"name":5,"class":6}]